中国报告大厅网讯,全球生物医药领域迎来重要合作进展:三生制药(01530.HK)宣布与跨国药企辉瑞达成战略协议,授权其自主研发的PD1/VEGF双特异性抗体SSGJ707在全球范围内的开发及商业化权益。此次交易不仅创下中国创新药出海的新里程碑,更标志着三生制药在肿瘤治疗领域的国际化布局取得突破性进展。 一、重磅合作重塑全球市场格局 中国报告大厅发布的《2025-2030年中国制药行业运营态势与...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.